Executive leadership at KIORA PHARMACEUTICALS.
Board of directors at KIORA PHARMACEUTICALS.
Research analysts covering KIORA PHARMACEUTICALS.
Recent press releases and 8-K filings for KPRX.
Kiora Pharmaceuticals Announces Q3 2025 Results and Clinical Trial Progress
KPRX
Earnings
Guidance Update
New Projects/Investments
- Kiora Pharmaceuticals, Inc. (KPRX) announced its third quarter 2025 financial results and provided an update on its clinical development pipeline on November 7, 2025.
- The company reported a net income of $26,806 for the third quarter of 2025, a significant improvement compared to a net loss of $3.4 million in the third quarter of 2024.
- Kiora ended the quarter with $19.4 million in cash, cash equivalents, and short-term investments, maintaining a projected cash runway into late 2027.
- Research and Development (R&D) expenses were $2.7 million in Q3 2025, partially offset by $1.7 million in reimbursable expenses from Théa.
- Both Phase 2 clinical trials, KLARITY (KIO-104 for retinal inflammation) and ABACUS-2 (KIO-301 for vision restoration), are actively recruiting and dosing patients.
Nov 7, 2025, 11:02 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more